Medicenna (MDNA) | Financial Analysis & Statements
Medicenna Therapeutics Corp. Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Sep 2023Income Metrics
Revenue
0
Operating Income
-5.4M
Net Income
-3.7M
EPS (Diluted)
$-0.05
Balance Sheet Metrics
Total Assets
27.7M
Total Liabilities
4.3M
Shareholders Equity
23.4M
Debt to Equity
0.18
Cash Flow Metrics
Revenue & Profitability Trend
Medicenna Income Statement From 2020 to 2023
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Goods Sold | - | - | - | - |
| Gross Profit | - | - | - | - |
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses | ||||
| Research & Development | 9.3M | 14.7M | 10.9M | 5.9M |
| Selling, General & Administrative | 7.0M | 7.7M | 6.5M | 2.5M |
| Other Operating Expenses | - | - | - | -125.4K |
| Total Operating Expenses | 16.3M | 22.4M | 17.4M | 8.2M |
| Operating Income | -16.3M | -22.5M | -17.4M | -8.2M |
| Operating Margin % | 0.0% | 0.0% | 0.0% | 0.0% |
| Non-Operating Items | ||||
| Interest Income | 914.0K | 69.0K | 314.0K | 6.7K |
| Interest Expense | - | - | - | - |
| Other Non-Operating Income | 5.3M | -173.0K | -208.0K | -39.0K |
| Pre-tax Income | -10.0M | -22.6M | -17.3M | -8.3M |
| Income Tax | - | - | - | - |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -10.0M | -22.6M | -17.3M | -8.3M |
| Net Margin % | 0.0% | 0.0% | 0.0% | 0.0% |
| Key Metrics | ||||
| EBITDA | -21.6M | -22.3M | -17.1M | -8.2M |
| EPS (Basic) | $-0.16 | $-0.42 | $-0.35 | $-0.26 |
| EPS (Diluted) | $-0.16 | $-0.42 | $-0.35 | $-0.26 |
| Basic Shares Outstanding | 64736493 | 54286671 | 49661776 | 31899640 |
| Diluted Shares Outstanding | 64736493 | 54286671 | 49661776 | 31899640 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Medicenna Balance Sheet From 2019 to 2023
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 33.6M | 20.5M | 30.4M | 22.7M | 2.4M |
| Short-term Investments | - | 0 | 10.0M | 15.0M | - |
| Accounts Receivable | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Other Current Assets | - | - | - | - | - |
| Total Current Assets | 36.4M | 23.4M | 42.1M | 37.9M | 5.1M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | - | - | 32.0K | 0 | - |
| Goodwill | 61.0K | 65.0K | 71.0K | 76.3K | 81.2K |
| Intangible Assets | - | - | - | 76.3K | 81.2K |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | - | - | - | - | - |
| Total Non-Current Assets | 61.0K | 65.0K | 103.0K | 144.0K | 81.2K |
| Total Assets | 36.4M | 23.5M | 42.3M | 38.0M | 5.2M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 1.6M | 1.7M | 2.2M | 456.2K | 802.0K |
| Short-term Debt | - | - | 34.0K | 35.3K | - |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | - | - | - | - |
| Total Current Liabilities | 3.8M | 2.6M | 4.1M | 1.8M | 802.0K |
| Non-Current Liabilities | |||||
| Long-term Debt | - | - | 0 | 32.0K | - |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | - | - | - | - | - |
| Total Non-Current Liabilities | 3.2M | 0 | 0 | 32.0K | 174.4K |
| Total Liabilities | 7.0M | 2.6M | 4.1M | 1.8M | 976.5K |
| Equity | |||||
| Common Stock | 100.9M | 83.7M | 79.6M | 56.6M | 16.6M |
| Retained Earnings | -81.0M | -70.9M | -48.4M | -31.1M | -22.8M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 29.5M | 20.8M | 38.1M | 36.1M | -6.0M |
| Key Metrics | |||||
| Total Debt | 0 | 0 | 34.0K | 67.3K | 0 |
| Working Capital | 32.6M | 20.8M | 38.0M | 36.0M | 4.3M |
Balance Sheet Composition
Medicenna Cash Flow Statement
No cash flow data available.
Medicenna Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-0.98
Forward P/E
-0.75
Price to Book
0.47
PEG Ratio
0.02
Profitability Ratios
Return on Equity
-34.08%
Return on Assets
-27.57%
Financial Health
Current Ratio
7.49
Debt to Equity
0.00
Per Share Data
EPS (TTM)
$-0.16
Book Value per Share
$0.34
Revenue per Share
$0.00
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| MDNA | 10.9M | -0.98 | 0.47 | -34.08% | 0.00% | 0.00 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Alnylam | 41.9B | 132.73 | 52.09 | 73.28% | 8.45% | 376.19 |
| Royalty Pharma plc | 29.4B | 27.89 | 3.29 | 13.20% | 32.42% | 92.33 |
| Insmed | 31.0B | -22.40 | 40.88 | -249.28% | -210.54% | 101.43 |
Financial data is updated regularly. All figures are in the company's reporting currency.